Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization

Area of Science:

• Oncology
• Allergy and Immunology
• Pharmacology

Background:

• Oxaliplatin hypersensitivity (OXS) poses a significant clinical challenge in managing patients with oxaliplatin-sensitive cancers.
• Understanding the characteristics of OXS is crucial for optimizing treatment strategies and patient management.

Purpose of the Study:

• To analyze patient demographics and clinical presentation of oxaliplatin hypersensitivity (OXS).
• To evaluate the utility of skin testing for risk stratification in OXS.
• To assess the outcomes of drug desensitization protocols for patients with OXS.

Main Methods:

• Retrospective analysis of 48 patients with OXS over a 5-year period.
• Evaluation of clinical reaction patterns and immediate hypersensitivity skin testing.
• Performance of drug desensitizations using continuous intravenous protocols tailored to patient history and skin test results.

Main Results:

• OXS occurred in patients with various malignancies, with a median onset at the 8th course of therapy.
• Neurologic and systemic symptoms were more frequent in OXS compared to other platinum agents; drug-induced thrombocytopenia and hemolytic anemia were observed.
• Skin testing was positive in 59% of patients and correlated with increased hypersensitivity reaction risk during desensitization; 200 desensitizations were safely completed.

Conclusions:

• Oxaliplatin hypersensitivity shares similarities with other platin agents but exhibits distinct characteristics in onset, patient sex, tumor type, and specific adverse events like thrombocytopenia and hemolytic anemia.
• Skin testing is a valuable tool for risk stratification in patients with OXS.
• Drug desensitization is a safe and effective management strategy for OXS, with all procedures completed successfully.